Study S000903

A Randomised, Open-label, Single Centre, Three Period Cross-over Trial in Healthy Subjects Comparing the Pharmacokinetic Profiles After Single Dose Administration of Liraglutide at Three Different Injection Sites

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01513525
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 21
Start: 2007-02
Primary completion: 2007-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2006-004670-27

Registered primary outcomes

Area under the Curve (AUC) of liraglutide for each injection site []

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023463	Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. Kapitza C, Journal of clinical pharmacology	2011	Other	PMID 20671294 DOI	registry reference RESULT:20671294